ODTXOdyssey Therapeutics, Inc.
$18.09
$18.09
$15.5652 weeks$28.84
The financials
Odyssey Therapeutics, Inc. by the numbers
Odyssey Therapeutics, Inc. (ODTX) reported revenue of $0 in Q2 2026 (quarter ended Jun 30, 2026), down 100% from the same quarter a year earlier. That came with net loss of $53M. The next results filing is expected around Nov 3, 2026, a quarter after the last one.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $0 | $1.9M | to a loss |
| Operating income | −$55M | −$39M | n/a |
| Net income | −$53M | −$38M | n/a |
| Diluted EPS | −$1.74 | −$39.37 | n/a |
Biotechnology
The closest names by size in the same industry